Covid-19: DCGI gives nod to Serum Institute of India to resume clinical trial of...

The DCGI, however, put certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which have to be “scrupulously” followed by Serum Institute of India (SII).

from Hindustan Times - india https://ift.tt/2ZJfzBT

Share: